Renal and liver injury following the treatment of COVID-19 by remdesivir

• Main Authors: Mohsen Mohammad Rahimi (Author), Elham Jahantabi (Author), Behzad Lotfi (Author), Mehdi Forouzesh (Author), Rohollah Valizadeh (Author), Saman Farshid (Author)
• Format: Book
• Published: Society of Diabetic Nephropathy Prevention, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2251-8363; 2251-8819; 10.34172/jnp.2021.10
• Keywords: remdesivir; covid-19; renal injury; liver injury; acute kidney injury; end-stage renal disease; Pathology; RB1-214; Internal medicine; RC31-1245; Other systems of medicine; RZ201-999
• Source: Journal of Nephropathology, Vol 10, Iss 2, Pp e10-e10 (2021)

Remdesivir initially was intravenously administrated to treat the Ebola disease however right now it has been administered to treat COVID-19 in some countries. However it is necessary to find the exact effect of remdesivir in patients with COVID-19. Remdesivir solution is administered with a cyclodextrin carrier that filters solely by the glomeruli; thereby patients with abnormal renal function cannot eliminate it quickly; therefore, remdesivir can lead to renal failure or liver dysfunction during therapeutic process of COVID-19. Assessment of renal function in patients with COVID-19 who have acute kidney injury (AKI) or end-stage renal disease is fundamental.